Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMA: Rituximab Maintenance in Advanced Follicular Lymphoma
NCT00140582Phase 3Completed
- Sponsor
- Lymphoma Study Association
- Start
- Dec 2004
- Primary completion
- May 2007
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of rituximab in follicular lymphoma (FL) (2 arms), sponsored by Lymphoma Study Association. Primary endpoint: Progression Free Survival at 10 years. Started Dec 2004; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00140582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00140582.